36 results about "Drug content" patented technology

The present application belongs to the technical field of pharmaceutical preparations, and specifically provides a compound SYN045 soft capsule and a preparation method thereof. The present application adopts a fixed proportion of plant oil and polyoxyethylene glyceryl oleate combination to prepare the content, which helps to reduce the degradation of SYN045 in the content drug solution, ensures the stability of the active ingredient, and obtains a compound SYN045 soft capsule with good drug dissolution, high drug content, low impurity generation, and high bioavailability. Further, through prescription optimization of the soft capsule shell, a fixed proportion of plasticizer is selected, the mass ratio of glycerol and sorbitol is 1:2-3, the transfer of the compound SYN045 to the soft capsule shell is reduced, and thus the quality stability problem of the soft capsule preparation product during drug storage is solved.

The present invention relates to a pharmaceutical composition which does not undergo rapid initial burst release of a drug by comprising sustained release microspheres consisting of texipatide or a pharmaceutically acceptable salt thereof, an initial burst release inhibitor, and a biodegradable polymer, has a high drug content with respect to particle size, and has high bioavailability, thus, the composition can minimize patient pain and inflammatory response that may occur when administered to a human body, and thus can be effectively used in the prevention or treatment of diabetes, beta cell dysfunction, hypertension, hyperlipidemia, obesity, and non-alcoholic steatohepatitis.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

The invention provides a medicine content detection method combining a respiration simulation device and HPLC (High Performance Liquid Chromatography), which relates to the technical field of medicine detection and comprises the following steps: establishing a mathematical expression of a target medicine net peak area and a target medicine concentration under each respiration parameter combination and a mapping relation between the respiration parameter combination and a target medicine reference peak area; therefore, the target drug net peak area of the to-be-detected gas is determined, a plurality of similar breathing parameter combinations similar to the breathing state under the current breathing parameter combination are screened out, and the accurate value of the target drug concentration of the to-be-detected gas is determined by combining the corresponding confidence coefficient, so that the accuracy of the detection result is ensured, and the detection efficiency is improved. A mathematical expression for solving the target drug concentration under the current breathing parameter combination is established without multiple calibration tests, so that the workload is greatly reduced, and the drug concentration detection efficiency is improved.

The invention discloses a preparation method of inositol nicotinate tablets, and belongs to the technical field of pharmaceutical preparations. By optimizing the existing process and coating components, stable dissolution of drugs is realized, and the method comprises the following steps: dispersing inositol nicotinate in mixed oil to prepare an oil phase, mixing and emulsifying the oil phase and a water phase, performing spray drying to obtain drug milk powder, coating the drug milk powder with modified chitosan, and directly tabletting the coated drug milk powder and auxiliary materials. The preparation method comprises the following steps: uniformly dispersing inositol nicotinate in mixed oil to promote the inositol nicotinate to maintain the uniformity of the drug content in the subsequent process, and adsorbing solid particles on the surfaces of drug-containing oil drops through an emulsification technology to protect the drug components; coating components are reasonably designed, so that fixed-point release of the medicine is realized, the medicine is endowed with anti-pressure ability, and the medicine can be directly tableted; and the coated medicine particles are mixed with auxiliary materials and then are directly tableted, so that the process is simplified, and the coating structure of the medicine particles is protected at the same time. The preparation method can prepare the inositol nicotinate tablet with stable drug dissolution, and the inositol nicotinate tablet is good in taste and small in stimulation to gastric mucosa.

The invention relates to the technical field of particle raw material stirring and mixing, in particular to a compound dibazol hydrochlorothiazide capsule raw material pretreatment stirring and mixing device which comprises a plurality of treatment frames which are evenly distributed from top to bottom and provided with upward openings, discharging openings are formed in the bottoms of the treatment frames, and stirring mechanisms are installed in the treatment frames; the device adopts a manner of matching layered laying and alternate stacking, active ingredients are independently stirred and flattened, then the active ingredients and auxiliary materials are stacked layer by layer, the active ingredients are uniformly attached to the surfaces of the auxiliary materials through throwing, and multi-stage gradual dilution is carried out, so that the problem that the active ingredients are easy to disperse and non-uniform when being directly mixed can be solved, the medicine content accuracy is improved, and the medicine quality is improved. And the components of each capsule are uniform and reach the standard.

The invention discloses timolol maleate gel emplastrum and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The gel paste comprises timolol maleate, a gel skeleton, a cross-linking agent, a cross-linking regulator, a filler, a penetration enhancer, a tackifier, a humectant, a pH regulator, a preservative and purified water. The preparation method comprises the following steps: preparing an oil phase; preparing the medicine and the water-soluble auxiliary materials into a solution; the tackifier adopts methyl acrylate / acrylic acid 2-ethylhexyl copolymer resin emulsion as a single phase; mixing the oil phase with the solution and the tackifier to obtain uniform gel paste with better ductility; and uniformly coating the paste on a backing layer, covering with a protective layer, and packaging to obtain the timolol maleate gel emplastrum. Through optimized prescription composition and process, the preparation has the characteristics of stable drug content and good skin adhesion, can realize continuous transdermal release of drugs, and is especially suitable for long-term safe treatment of infantile hemangioma.

The invention discloses a method for verifying combination of a small molecule drug and a cell target protein, and belongs to the field of cytobiology and molecular biology. The method comprises the following steps: combining a small molecule drug with a cell target protein, and reducing the content of a free drug; the primary antibody is combined with cell protein to form a primary antibody complex; capturing a primary antibody complex by the PVDF membrane for incubating the secondary antibody; taking out the PVDF membrane, cleaning, and splitting miscellaneous protein in the solution to dissociate residual drugs; and detecting the amount of residual free drugs by HPLC, and analyzing data. The method solves the problem that small molecule-protein binding is difficult to directly detect in a traditional method, and the sensitivity is improved through combination of immunocapture and liquid chromatography or mass spectrometry quantitative detection. According to the method, a trace reagent system is adopted, the dosage of a single sample antibody is reduced by 70%, the PVDF membrane can be repeatedly used for 3-5 times, and the comprehensive detection cost is reduced by 60-80%. Various drug properties can be adapted (by adjusting lysis conditions such as pH / temperature).

The application relates to the technical field of atomizers, in particular to an atomizing device which comprises a cylinder body and a cover body, a separation sleeve, a liquid storage tank, a heater and an atomizing sheet, the liquid storage tank is fixed on the cover body, and a liquid outlet assembly is fixedly connected to the liquid storage tank. The liquid storage tank utilizes negative pressure to store liquid medicine in the liquid storage cavity, so that the liquid medicine in the liquid storage cavity is basically at a certain height during use. When the atomizing sheet is started, the atomized mist is overflowed from the rear liquid medicine through the upper film sheet, and then is discharged through the exhaust assembly, and in the process, since the height of the liquid medicine is basically constant, the drug content carried by the mist after passing through the liquid medicine is basically consistent, so that the stability of the drug content in the mist atomized by the atomizer is improved.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a mononitrate isosorbide oral dissolving film and a preparation method thereof. The mononitrate isosorbide oral dissolving film preparation is composed of a drug-containing layer and isolation layers which are compounded on the upper and lower surfaces of the drug-containing layer. The drug-containing layer comprises the following raw materials in percentage by mass: cyclodextrin-encapsulated mononitrate isosorbide 10-60%, film-forming material 20-80%, plasticizer 0-20% and auxiliary material 0-10%. The isolation layer comprises the following raw materials in percentage by mass: film-forming material 70-100%, plasticizer 0-30% and auxiliary material 0-10%. The mononitrate isosorbide oral dissolving film prepared by the application has the advantages of smooth appearance, good taste, uniform drug content, rapid dissolution under the action of saliva after entering the mouth, and further release and absorption, which greatly improves the drug administration compliance and solves the problem of surface crystallization of mononitrate isosorbide after long-term storage.

The present invention relates to a pharmaceutical composition which does not undergo rapid initial burst release of a drug by comprising sustained release microspheres consisting of canagliflozin or a pharmaceutically acceptable salt thereof, an initial burst release inhibitor, and a biodegradable polymer, has a high drug content with respect to particle size, and has high bioavailability, thus, it is possible to minimize patient pain and inflammatory response that may occur when administered to a human body, and thus it is effective for preventing or treating diabetes, beta cell dysfunction, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or Alzheimer's disease.

This invention discloses a tangential flow filtration separation device and a method for determining the drug content of liposomal drugs, relating to the field of liposomal drug filtration and determination technology. The device includes a filtration separation component, a gas control component, a drive component, and system piping and valve components. The filtration separation component includes a porous membrane filtration unit, with the inner cavity of the membrane forming a mother liquor flow path, and the outer cavity connected to a filtrate collection unit. The drive component is connected to the mother liquor flow path, and the gas control component is also connected to the mother liquor flow path. The system piping and valve components connect the filtration separation component, the gas control component, and the drive component to form a closed-loop flow path. This invention solves the problems of existing methods, such as difficulty in efficiently and stably separating free drugs from liposomal components, cumbersome operation, easy liposomal leakage, and sample loss and dilution, which seriously affect the accuracy of detection.

The invention belongs to a sewage monitoring technology, and particularly provides a multi-source risk aggregation tracing method and system for sewage poison monitoring, and the tracing method comprises the steps: A1, collecting the current monitoring data of sewage at each point (i, j), the data comprising a poison content detection value D (i, j), time and a place; a2, obtaining a traceability matrix M (i, j) according to the detection value matrix Dk (i, j) of each point location in N rounds; a3, a point location with a value greater than 0 in the matrix M (i, j) is a traceable point location; and A4, visually displaying the point location of the traceability and the mark of the M value corresponding to the point location. The method has the advantages of accurate traceability and the like.

This invention discloses the application of fluorescent carbon dots for mycophenolic acid detection, relating to the field of drug content detection technology. The carbon dot preparation method includes the following steps: adding β-cyclodextrin and L-phenylalanine to deionized water, ultrasonically mixing, and performing a hydrothermal reaction to obtain a reaction solution; cooling to room temperature, and then sequentially filtering, dialyzing, and freeze-drying to obtain fluorescent carbon dots for mycophenolic acid detection. This invention uses water as the reaction solvent and employs a one-step hydrothermal method to synthesize fluorescent carbon dots, which have been successfully applied to the sensing and determination of mycophenolic acid with good results. It offers advantages such as convenient construction, high sensitivity, good specificity, and ease of use. This invention solves the problems of complex operation, high cost, and low accuracy in existing methods for mycophenolic acid content detection.

This invention belongs to the field of pharmaceutical formulation technology and relates to a bisoprolol fumarate tablet with long-term storage stability and its preparation method. The formulation of the bisoprolol fumarate tablet of this invention includes bisoprolol fumarate, filler, disintegrant, lubricant, binder, composite stabilizer, and appropriate amount of water; the preparation method includes steps such as raw material pretreatment, composite stabilizer pretreatment, binder preparation, granulation, total mixing, tableting, and coating. This invention significantly improves the long-term storage stability of bisoprolol fumarate tablets through the synergistic effect of the three components in the composite stabilizer, combined with an optimized preparation process, effectively reducing problems such as drug content decline, increase of related substances, and abnormal physical properties of tablets, ensuring the efficacy and safety of the drug.

In order to develop the natural plant ointment with anti-inflammatory, antipruritic and sunscreen functions, anti-inflammatory components are screened through a xylene induced mouse ear swelling experiment, and the antipruritic effect is evaluated and the proportion is optimized through hyaluronidase and dextran induced pruritic experiments. Results show that the 95% alcohol extract of the chicory roots has the best anti-inflammatory effect; when the ratio of the No.2 alkanet alcohol extract to the No.1 alkanet water decoction to the cichorium intybus stem alcohol extract to the vernonia esculenta alcohol extract to the perilla frutescens water extract is 1: 3: 8: 3: 5, the hyaluronidase inhibition rate reaches 31.62%, and the itching relieving effect is optimal. And finally determining that the minimum effective drug content of the ointment is 0.40% of the total drug content, wherein the ratio of the chicory stem alcohol extract to the 95% alcohol extract of the second lithospermum to the alcohol extract of the vernonia anthelmintica seeds is 8: 1: 3. The O / W type ointment has remarkable anti-inflammatory and itching-relieving effects and has certain ultraviolet-proof capability. The research provides a scientific basis for developing safe and effective natural plant itching-relieving sunscreen products.

The application provides an ambroxol oral dissolving film composition, a preparation method and application thereof. The ambroxol oral dissolving film composition comprises an active drug, a film forming material and a taste masking agent, and the active drug is 2-amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl) benzylamine and / or a pharmaceutically acceptable salt thereof, for example, ambroxol hydrochloride. The ambroxol oral dissolving film composition provided by the application has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without drinking water, and fast oral absorption speed. Moreover, the ambroxol oral dissolving film composition has the advantages of simple process, high drug loading, good drug content uniformity, and good market prospect.

This invention relates to a 30 mg bilayer biphasic-release tablet containing merogabarine or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The tablet is a bilayer tablet consisting of an immediate-release layer and a sustained-release layer, wherein the immediate-release layer accounts for 20%–35% of the total drug content, and the sustained-release layer accounts for 65%–80% of the total drug content. The sustained-release layer contains hydroxypropyl methylcellulose K15M or hydroxypropyl methylcellulose K100M and ethylcellulose. Under the conditions of the second method for release determination in the current edition of the Chinese Pharmacopoeia, the tablet has a predetermined 24-hour release window in any of the media selected from pH 1.2, pH 4.5, and pH 6.8, and maintains a small difference in media values ​​at 8 hours and 12 hours, making it suitable for development into an oral sustained-release formulation for once-daily administration.

The invention discloses an injection for preventing and treating delirium of ICU (intensive care unit) critical and cancer postoperative patients as well as a preparation method and application of the injection, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following components in percentage by weight: 0.001 to 0.5 percent of melatonin receptor stimulant, 530 percent of oil for injection, 0.55 percent of phospholipid, 00.5 percent of co-emulsion, 0.55 percent of isoosmotic adjusting agent, 0.011.0 percent of pH (Potential of Hydrogen) adjusting agent and the balance of water for injection, and the pH is 5.010.0. The preparation process comprises the steps of oil phase preparation, water phase preparation, emulsification, high-pressure homogenization, sterilization and the like. The average particle size (D50) of the injection is 100350nm, the content of large emulsion particles with the particle size of 5 microns is 0-0.05%, the release rate within one hour is not lower than 80%, and the main drug content within 24 months of validity is not lower than 90%. According to the invention, the drug treatment accessibility of existing ICU severe illness and cancer postoperative delirium is realized. The product takes effect quickly after administration, can realize smooth transition from short-term injection administration to oral administration in a recovery phase after ICU / severe illness operation, and has a remarkable clinical compliance advantage.

This invention provides a cariprazine orally disintegrating film composition, its preparation method, and its application. The orally disintegrating film composition comprises an active ingredient, a film-forming material, and a plasticizer, wherein the active ingredient is selected from one or more mixtures of cariprazine, pharmaceutically acceptable salts of cariprazine, and their inclusion compounds. The orally disintegrating film composition of this invention has the advantages of thin thickness, good taste, stable properties, immediate dissolution in the oral cavity without water, and rapid oral absorption. It also features a simple process, high drug loading capacity, and good drug content uniformity. The orally disintegrating film composition of this invention helps improve medication compliance, medication retention, and vomiting in patients with schizophrenia, and is particularly suitable for patients with swallowing difficulties, showing promising market prospects.

The present invention provides a pharmaceutical composition comprising semaglutide or a salt thereof, a bioavailability improver, and sustained-release microspheres made of a biodegradable polymer, exhibiting high bioavailability and stable drug release characteristics over a long period of time, and a pharmaceutical composition comprising semaglutide or a salt thereof and sustained-release microspheres made of a biodegradable polymer, exhibiting safe drug release characteristics with high drug content and low initial release, and a method for producing the sustained-release microspheres. [Solution] A pharmaceutical composition for the prevention or treatment of diabetes, type 2 diabetes, preservation of beta-cell function, obesity, non-alcoholic steatohepatitis, and degenerative neurological diseases, comprising semaglutide or a salt thereof, a bioavailability improving agent, and a biodegradable polymer-based sustained-release microglobules, wherein the semaglutide or a salt thereof is present in an amount of 8% by weight or more of semaglutide relative to the total weight of the microglobules, and the bioavailability improving agent is present in an amount of 2.5% to 250% by weight relative to the weight of semaglutide, and a method for producing the same.

The invention relates to the technical field of soluble microneedles, in particular to an epinephrine soluble microneedle, a preparation method and application thereof and a transdermal patch. The epinephrine soluble microneedle comprises a needle tip and a substrate, and the needle tip is prepared from the following raw materials in parts by weight: 10-25 parts of an epinephrine compound, 1-2 parts of polyvinyl alcohol, 2-3 parts of polyvinylpyrrolidone and 30-50 parts of water; the substrate is prepared from the following raw materials in percentage by mass: 10 to 30 percent of chondroitin sulfate compound, 10 to 30 percent of dextran and 40 to 80 percent of water. The epinephrine soluble microneedle disclosed by the invention has the advantages of relatively high drug delivery efficiency, relatively good mechanical property and formability, and relatively high stability and drug content.

The present invention relates to a triazole drug suspension, a preparation method therefor, and use thereof. The triazole drug suspension of the present invention comprises a therapeutically effective amount of itraconazole, a surfactant, solvent water, an osmotic pressure regulator, a metal complexing agent, and a pH regulator, wherein the mass ratio of itraconazole to the surfactant is 5:1-15:1. Itraconazole has a D10 particle size of greater than or equal to 0.5 μm, a D50 particle size of 1.5-3.5 μm, and a D90 particle size of less than or equal to 6.0 μm. The concentration of free itraconazole in the suspension is not less than 0.04 μg / ml. The suspension of the present invention has a suitable free-state drug content and a suitable granular drug particle size distribution, enabling, after the suspension of the present invention is administered by means of inhalation, the drug to be rapidly absorbed by a target part and to act, and maintaining sustained and slow release. While a therapeutic dose is maintained, the frequency of administration is reduced, thereby improving the safety of drug administration.

This utility model discloses a split-type navel patch, belonging to the field of navel patch technology. The utility model includes a main patch and a cotton ball. A support ring is fixed at the center of the top of the main patch, and the support ring and the main patch cooperate to form a placement groove. The cotton ball is installed in the placement groove and has a connecting part. The top of the connecting part has a groove, and the center of the groove has a protrusion with a round hole at the top. By separating the medicated oil, cotton ball, and main patch, this utility model allows users to flexibly adjust the dosage of medicated oil applied to the cotton ball according to the patient's specific physical condition and the severity of their condition. Compared to the fixed drug content of traditional navel patches, this ensures that patients receive the most suitable drug dosage each time they use the navel patch, significantly improving the targeting and effectiveness of the treatment plan and providing patients with higher-quality healthcare services.

This invention provides a furosemide-triamterene compound thermosensitive hydrogel oral formulation, its preparation method, detection method, and application, belonging to the field of veterinary formulation technology. The formulation, by mass percentage, comprises furosemide 0.2%-2.0%, triamterene 0.2%-2.0%, an adhesion thickener 0.5%-2.0%, a thermosensitive hydrogel matrix 15%-30%, and moisturizing stabilizers, flavoring agents, and preservatives. The gelation temperature is 28-32℃, the maximum adhesion force to the gastric mucosa is 0.15N-0.35N, and the adhesion work is 5mJ-15mJ. This invention employs a cold-dissolution method, a process free of organic solvents, and simultaneously determines the content of two drugs using HPLC. The formulation flows at 2-8°C and rapidly gels and adheres at 37°C, achieving synergistic diuresis and potassium balance maintenance. It features precise dosage, good palatability, and stable blood drug concentrations, making it suitable for preparing veterinary drugs for canine and feline diuresis, swelling reduction, and potassium balance maintenance. This invention solves the problems of inaccurate dosage, poor compliance, and lack of quality control in existing pet diuretic preparations, ensuring stable and controllable quality and suitability for large-scale production.

This invention discloses a drug content detection device, relating to the field of drug detection technology. It includes a device housing and an operation panel. The top of the housing has a printing component, and the bottom has a detection port. The operation panel is mounted on the housing, and a heat dissipation groove is located on the rear side of the housing. It also includes a mounting shell fixed to the outside of the housing. Rectangular slots communicating with the mounting shell are provided at four positions (front, back, left, and right). Two transmission rods are symmetrically arranged inside the mounting shell, and both ends of the two transmission rods are connected to anti-drop units. This invention utilizes multiple retractable anti-drop plates (first and second types) to extend simultaneously during use, providing comprehensive protection for the top, bottom, and sides of the housing. This effectively buffers the impact of accidental drops or collisions, reducing the risk of damage to the precision detection components inside the device.

The invention provides a method for determining the release degree of an insoluble drug. The method comprises the following steps: S1, adding an adsorption material into a release medium; s2, adding a to-be-detected indissolvable pharmaceutical preparation into the release medium; s3, dissolving out at a preset temperature under a stirring condition; s4, sampling at a plurality of time points and measuring the content of the medicine in the release medium; s5, calculating the drug release degree according to the drug contents at the multiple time points. According to the method, the adsorption material is added into the release medium, free drugs are rapidly adsorbed, and a leakage groove condition is formed and maintained; the in-vivo drug dissolution-absorption process is simulated, and the release behaviors of various insoluble drugs are truly reflected; on the basis that the advantages of macroporous adsorption resin are reserved, the adsorption behavior is controllable through functionalization treatment, damage to the drug structure is reduced, and therefore the distinguishability of a release curve is higher.

A method of detecting a drug content indicator of a non-viral nucleic acid vector composition comprises contacting a permeable nucleic acid dye with a non-viral nucleic acid vector (e.g., mRNA-LNP) composition for labeling. The drug content index is calculated by measuring the fluorescence generated by the free nucleic acid of the nucleic acid carrier and the fluorescence generated by the external adsorbed nucleic acid and the internal encapsulated nucleic acid of the non-viral nucleic acid carrier at the single particle level. Drug content indexes comprise drug loading capacity, encapsulation efficiency and the like. The method optionally further comprises: treating the sample with a nuclease before or after labeling of the permeable nucleic acid dye, and determining the fluorescence condition of the non-viral nucleic acid vector composition after nuclease treatment; or contacting the non-permeable nucleic acid dye with the sample, and determining the fluorescence condition of the non-viral nucleic acid vector composition after contact.

This invention discloses an improved reservoir-type vaginal ring. The drug is loaded as a drug-carrying core by mixing it with silicone rubber, and the core is coated with a controlled-release layer made of pure silicone rubber. The drug-carrying core contains a developing agent and a dispersant. The developing agent includes barium sulfate, titanium dioxide, iodotram, iodofol, iopromide, iodophenylhexamol, and iodophenyl ester. The dispersant includes methyl silicone oil, phenyl silicone oil, vinyl silicone oil, hydrogen-containing silicone oil, and glycerin. This invention combines the advantages of existing extrusion and molding methods, effectively controlling the size and regularity of the drug-carrying core of the reservoir-type vaginal ring, ensuring stable and controllable drug content. It can effectively improve the product deformation problems caused by cutting, external force, and hot-pressing vulcanization processes in existing co-extrusion processes.

The application provides a cariprazine orally dissolving film composition, a preparation method and application thereof. The orally dissolving film composition comprises an active ingredient, a film forming material and a plasticizer, wherein the active ingredient is selected from a mixture of one or more of cariprazine, a pharmaceutically acceptable salt of cariprazine and an inclusion compound thereof. The orally dissolving film composition has the advantages of thin thickness, good taste, stable property, instant dissolving in the oral cavity without drinking water, fast oral absorption speed, simple process, high drug loading, good drug content uniformity, and the like. The orally dissolving film composition helps to improve the poor compliance, hiding and spitting of patients with schizophrenia, and is particularly suitable for patients with difficulty in swallowing, and has a good market prospect.